These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10700868)

  • 1. Multiple myeloma: monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term follow-up.
    Carlebach M; Amiel A; Gaber E; Radnay J; Manor Y; Fejgin M; Lishner M
    Cancer Genet Cytogenet; 2000 Feb; 117(1):57-60. PubMed ID: 10700868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
    Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
    Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous detection of BCL-2 protein, trisomy 12, retinoblastoma and P53 monoallelic gene deletions in B-cell chronic lymphocytic leukemia by fluorescence in situ hybridization (FISH): relation to disease status.
    Lazaridou A; Miraxtsi C; Korantzis J; Eleftheriadis N; Christakis JI
    Leuk Lymphoma; 2000 Feb; 36(5-6):503-12. PubMed ID: 10784395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.
    Chang H; Yeung J; Qi C; Xu W
    Br J Haematol; 2007 Aug; 138(3):324-9. PubMed ID: 17555471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of the retinoblastoma gene in multiple myeloma.
    Dao DD; Sawyer JR; Epstein J; Hoover RG; Barlogie B; Tricot G
    Leukemia; 1994 Aug; 8(8):1280-4. PubMed ID: 8057662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.
    Chang H; Qi C; Yi QL; Reece D; Stewart AK
    Blood; 2005 Jan; 105(1):358-60. PubMed ID: 15339849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allelic deletions of cell growth regulators during progression of bladder cancer.
    Primdahl H; von der Maase H; Christensen M; Wolf H; Orntoft TF
    Cancer Res; 2000 Dec; 60(23):6623-9. PubMed ID: 11118045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of RB1 deletions by fluorescence in situ hybridization in malignant hematologic disorders.
    Juneau AL; Kaehler M; Christensen ER; Schad CR; Zinsmeister AR; Lust J; Hanson C; Dewald GW
    Cancer Genet Cytogenet; 1998 Jun; 103(2):117-23. PubMed ID: 9614909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of PTEN deletions and mutations in multiple myeloma.
    Chang H; Qi XY; Claudio J; Zhuang L; Patterson B; Stewart AK
    Leuk Res; 2006 Mar; 30(3):262-5. PubMed ID: 16112193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
    Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
    Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
    Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Investigation of the molecular changes in patients with multiple myeloma by fluorescence in situ hybridization].
    Yang RF; Li CM; Chen LJ; Qiu HR; Yang H; Liu P; Xu JR; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Oct; 27(5):567-70. PubMed ID: 20931539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
    Chen MH; Qi CX; Saha MN; Chang H
    Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A possible role of the P53 gene deletion as a prognostic factor in multiple myeloma.
    Ortega MM; Melo MB; De Souza CA; Lorand-Metze I; Costa FF; Lima CS
    Ann Hematol; 2003 Jul; 82(7):405-9. PubMed ID: 12783209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow.
    Petrackova A; Minarik J; Sedlarikova L; Libigerova T; Hamplova A; Krhovska P; Balcarkova J; Pika T; Papajik T; Kriegova E
    Br J Haematol; 2020 May; 189(4):e122-e125. PubMed ID: 32130732
    [No Abstract]   [Full Text] [Related]  

  • 16. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
    An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.
    Chavan SS; He J; Tytarenko R; Deshpande S; Patel P; Bailey M; Stein CK; Stephens O; Weinhold N; Petty N; Steward D; Rasche L; Bauer M; Ashby C; Peterson E; Ali S; Ross J; Miller VA; Stephens P; Thanendrarajan S; Schinke C; Zangari M; van Rhee F; Barlogie B; Mughal TI; Davies FE; Morgan GJ; Walker BA
    Blood Cancer J; 2017 Feb; 7(2):e535. PubMed ID: 28234347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors.
    Merten L; Agaimy A; Moskalev EA; Giedl J; Kayser C; Geddert H; Schaefer IM; Cameron S; Werner M; Ströbel P; Hartmann A; Haller F
    Am J Clin Pathol; 2016 Dec; 146(6):718-726. PubMed ID: 28028119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis, Biology, and Targeting of
    Flynt E; Bisht K; Sridharan V; Ortiz M; Towfic F; Thakurta A
    Cells; 2020 Jan; 9(2):. PubMed ID: 31991614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subclonal
    Shah V; Johnson DC; Sherborne AL; Ellis S; Aldridge FM; Howard-Reeves J; Begum F; Price A; Kendall J; Chiecchio L; Savola S; Jenner MW; Drayson MT; Owen RG; Gregory WM; Morgan GJ; Davies FE; Houlston RS; Cook G; Cairns DA; Jackson G; Kaiser MF;
    Blood; 2018 Dec; 132(23):2465-2469. PubMed ID: 30373884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.